DAS181: A novel host directed approach to prevent and treat severe respiratory virus infections

Vaccines and virus specific antivirals are currently the main approaches to prevent and treat respiratory virus infections. DAS181, a novel inhaled sialidase fusion protein, has shown in vitro and in vivo activity against many subtypes and strains influenza virus including H7N9, H5N1. In addition DAS181 has shown in vitro and in vivo activity against parainfluenza virus strains (PIV-1, PIV-2, PIV-3 and PIV-4) virus and EV68, by inactivating the virus binding receptors. For parainfluenza, significant morbidity and mortality is observed in immunosuppressed transplant patients without any licensed vaccines or antiviral drugs. Recent data also suggests that DAS181 has activity against two important respiratory viruses, Respiratory syncytial virus (RSV) and Metapneumovirus. The host directed approach of DAS181 contrasts virus specific antivirals by potentially circumventing considerable issues related to antiviral drug resistance and prediction of strains required for vaccines. DAS181, an investigational drug is currently in phase 2 clinical trials of PIV infection. DAS181 has the potential to be utilized against a broad spectrum of severe respiratory infections. Preclinical and clinical data from studies of DAS181 will be presented.

Biography

Ronald Moss has been serving as the Chief Executive Officer of Ansun Biopharma Inc., since October 2012 and he has served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. He has held various executive positions in the pharmaceutical industry for over 20 years and played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. He has been involved in drug and vaccine development of products in infectious disease, allergy, neurology, dermatology, oncology, respiratory, transplant and autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. He has received his MD degree from Chicago Medical School, Residency in Pediatrics at SUNY Stony Brook and completed a Fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology.

Notes: